-transparent.png){kind=logo}
Navelbine (NVB) pharmacokinetics has been investigated in the dog after p.o. administration of increasing doses (0.5-8 mg/kg) and in the monkey after a single dose of 40 mg/ml. In the dog, NVB pharmacokinetic parameters, Cmax, tmax, AUC, t1/2 and Cl, were 49.0-1021.0 ng/ml, 1.14-3.69 h, 370.0-11754.5 ng/ml h, 19.3-64.3 h and 0.46-1.47 l/h/kg, respectively. As the dose increased, the plasma concentration peak appeared more slowly and t1/2 increased significantly with a marked reduction in Cl. Moreover, NVB pharmacokinetics in the dog exhibited significant dose-dependency as demonstrated by analysis of variance (ANOVA) of dose-normalized AUC and Cmax. Pharmacokinetic parameters estimated from monkey data were essentially the same as those of the dog (Cmax, 877.6 mg/ml; tmax, 1.14 h; AUC, 7004.8 ng/ml h; t1/2, 18.2 h) except for Cl (10.40 l/h/kg), which was about 10-fold that of the dog.
X J Zhou, and
H Landi, and
F Breillout, and
R Rahmani
January 1991,
Cancer chemotherapy and pharmacology,
X J Zhou, and
H Landi, and
F Breillout, and
R Rahmani
January 1990,
Bulletin du cancer,
X J Zhou, and
H Landi, and
F Breillout, and
R Rahmani
December 2011,
Veterinary dermatology,
X J Zhou, and
H Landi, and
F Breillout, and
R Rahmani
January 2002,
Tumori,
X J Zhou, and
H Landi, and
F Breillout, and
R Rahmani
June 1981,
American journal of veterinary research,
X J Zhou, and
H Landi, and
F Breillout, and
R Rahmani
September 1976,
Archives internationales de pharmacodynamie et de therapie,
X J Zhou, and
H Landi, and
F Breillout, and
R Rahmani
August 1991,
Anti-cancer drugs,
X J Zhou, and
H Landi, and
F Breillout, and
R Rahmani
January 1992,
European journal of drug metabolism and pharmacokinetics,
X J Zhou, and
H Landi, and
F Breillout, and
R Rahmani
January 1954,
Bollettino della Societa italiana di biologia sperimentale,
X J Zhou, and
H Landi, and
F Breillout, and
R Rahmani
March 1986,
Transplantation,
